Skip to content
    VRTX
    Earnings call· Jun 2026(Q2 FY26)

    VERTEX PHARMACEUTICALS INC / MA Q2 FY26 earnings call VRTX

    Aug 3, 2026 Source

    Executive summary

    Vertex Pharmaceuticals Q2 FY26 — Strong Commercial Momentum and Strategic Expansion

    Vertex delivered excellent Q2 FY26 performance, marked by robust commercial growth across its CF, heme, and pain franchises, alongside significant pipeline advancements in renal and type 1 diabetes. The company also announced the strategic acquisition of Crinetics Pharmaceuticals, establishing a fifth therapeutic pillar in rare endocrine diseases. While facing some gross margin and operating expense pressures, Vertex remains focused on disciplined investment and continued expansion.

    Highlights

    5

    • Total revenue grew 12% year-on-year.

    • ALYFTREK revenue exceeded $1 billion in the first half of 2026.

    • CASGEVY revenue grew 75% sequentially to $76 million in Q2 2026.

    • JOURNAVX revenue grew 70% sequentially to $50 million in Q2 2026.

    • Pove BLA for IgAN accepted by FDA with a November 30 PDUFA date.

    Concerns

    3

    • Gross margin stepped down to 85.6% in Q2 2026 due to product mix and manufacturing investments.

    • JOURNAVX gross-to-net normalization is now expected in H1 2027, delayed from prior expectations.

    • Full year 2026 non-GAAP operating expense guidance is now expected at the high end of the $5.65 billion to $5.75 billion range.

    Guidance & targets

    6
    CategoryTargetConfidence
    Full Year 2026 Total Revenue
    $13.1 billion to $13.2 billion
    high materiality
    High
    Full Year 2026 Non-CF Product Revenue
    $500 million or greater
    medium materiality
    High
    Full Year 2026 Gross Margin
    just under 86%
    medium materiality
    High
    Full Year 2026 Combined Non-GAAP Operating Expense
    $5.65 billion to $5.75 billion
    medium materiality
    High
    Full Year 2026 Non-GAAP Effective Tax Rate
    19.5% to 20.5%
    low materiality
    High
    Crinetics Acquisition Accretion
    Accretive to non-GAAP operating income
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Global CF
    Global CF revenue grew 11% year-over-year, with balanced growth across the U.S. and internationally. ALYFTREK exceeded $1 billion in revenue in the first half of 2026. US CF growth was driven by ALYFTREK uptake, TRIKAFTA performance, and higher net price. Ex-US CF growth was driven by ALYFTREK launches, timing of orders, and FX benefit.
    ALYFTREK H1 2026 Revenue: $1 billionUS CF Revenue Growth YoY: 9%Ex-US CF Revenue Growth YoY: 12%
    		—11%——
    CASGEVY (Heme)
    CASGEVY revenue grew 75% sequentially and over 150% year-over-year, in line with expectations. The product received FDA approval for pediatric patients aged 2 to 11. Patient initiations continue to build, with over 100 in Q2 2026, marking the third sequential quarter of this trend.
    Q2 2025 Revenue: $30 millionPatient Initiations Q2 2026: >100H1 2026 Infusions: More than all of 2025
    		$76 million>150%75%—
    JOURNAVX (Acute Pain)
    JOURNAVX generated $50 million in revenue, reflecting 70% sequential growth. Prescription growth is ahead of forecast, with approximately 535,000 prescriptions in Q2 2026. The product is on 1,400 hospital and 130 IDN pathways, and total covered lives reached 260 million, with 180 million having unrestricted access.
    Q2 2025 Revenue: $12 millionQ2 2026 Prescriptions: ~535,000H1 2026 Prescriptions: >900,000Q2 2026 New HCP Prescribers: ~18,000Hospital Pathways: 1,400IDN Pathways: 130Total Covered Lives: 260 millionUnrestricted Covered Lives: 180 million
    		$50 million—70%—

    Operational metrics

    14
    Gross Margin
    85.6%sequential step-down from Q1 FY26
    Q2 FY26

    Expected sequential step-down from Q1 2026, with full year expected just under 86%.

    Non-GAAP R&D Expense
    $889 million1% YoY increase
    Q2 FY26

    Reflects steady progress across multiple Phase III studies and earlier-stage pipeline.

    Non-GAAP SG&A Expense
    $520 million45% YoY increase
    Q2 FY26

    Driven primarily by commercial investment to build new businesses.

    Acquired IPR&D Expense
    $21 million
    Q2 FY26

    Recorded in the quarter.

    Non-GAAP Effective Tax Rate
    21.1%
    Q2 FY26

    Year-to-date non-GAAP effective tax rate was 20.4%, within guidance range.

    Non-GAAP EPS
    $4.735% growth versus prior year
    Q2 FY26

    Reflects strong revenue growth and investments in pipeline and commercial capabilities.

    Cash and Investments Balance
    $13.6 billion
    Q2 FY26

    Balance at the end of the quarter.

    Share Repurchase
    $455 million
    Q2 FY26

    Reflects ongoing commitment to returning value to shareholders.

    FX Benefit to Revenue
    170
    Q2 FY26

    Approximate benefit from foreign exchange rates on Q2 2026 revenue.

    Non-CF Product Revenue
    ~$200 million
    H1 FY26

    Combined revenue from CASGEVY and JOURNAVX in the first half of the year.

    JOURNAVX Prescription Duration (Hospital)
    ~5 daysnot changed since launch
    current

    Driven by institutional dynamics.

    JOURNAVX Prescription Duration (Retail)
    ~12-14 daysnot changed since launch
    current

    Driven by institutional dynamics.

    JOURNAVX Gross-to-Net Normalization
    H1 2027
    future

    Expected to normalize in line with other branded oral medicines, but now in the first half of 2027 due to higher PSP usage.

    Renal Field Force Nephrology Experience
    90%
    current

    Percentage of renal field force with nephrology experience, built with the breadth of the renal pipeline in mind.

    Industry KPIs

    4
    MetricValueDetails
    Launch access metrics260 millionlives
    Product franchise net sales$1 billionUSD
    Peak long term sales guidance$5 billionUSD
    Prescription volume new starts535,000prescriptions

    Deals & partnerships

    1
    Crinetics PharmaceuticalsAcquisition to establish a fifth pillar in rare endocrine diseases, adding innovative R&D pipeline and accelerating revenue growth.$8.8 billion net of cash acquired

    Definitive agreement to acquire Crinetics Pharmaceuticals. Crinetics' focus on serious endocrine diseases, high unmet need, validated targets, and well-understood causal biology makes it a strong strategic fit.

    Risks & headwinds

    4
    Gross margin pressure from product mix and manufacturing investmentsH2 2026

    Q2 2026 gross margin 85.6% (sequential step-down from Q1 2026)

    Mitigation: Management expects full year gross margin just under 86%, indicating these factors are incorporated into guidance.

    Delayed JOURNAVX gross-to-net normalizationH1 2027

    Normalization now expected H1 2027 (previously H2 2026)

    Mitigation: Maintaining PSP program to ensure patient access, educating physicians on quantity limits and prior authorizations, and securing broader payer coverage.

    Quarter-to-quarter revenue variability for CASGEVY and JOURNAVXongoing

    CASGEVY: 75% sequential growth in Q2; JOURNAVX: 70% sequential growth in Q2

    Mitigation: Management expects continued momentum and growth for both products, with variability reflecting timing of patient infusions and channel build.

    Reduced contribution from prior year US price increases and foreign exchange to CF growthH2 2026

    Q2 2026 revenue growth reflects ~170 basis point benefit from FX rates

    Mitigation: Company expects these factors to contribute less to growth in the second half of the year, focusing on continued ALYFTREK uptake, label expansion, and younger patient populations.

    What to watch in Q3 FY26

    5

    VX-828 CFTR modulator data

    H2 2026
    CurrentDosing completed in patient cohort
    TargetData readout

    Why it matters

    Will determine potential for next-gen CFTR modulator to beat ALYFTREK's high efficacy bar.

    VX-828, our next-generation 3.0 CFTR modulator recently completed dosing in the patient cohort and data are expected in the second half of this year.

    Q&A highlights

    8

    What signal led to the 80mg dose selection for Pove in pMN Phase III, and what are the current bottlenecks for JOURNAVX regarding formulary and payer dynamics?

    The DSMB selected the 80mg dose for Pove in pMN Phase III based on efficacy (PLA2R reduction) and safety data, consistent with prior RUBY-3 results. For JOURNAVX, prescription growth and hospital adoption are strong, but ongoing work is needed to secure final access elements and educate physicians on quantity limits/prior authorizations to reduce reliance on the PSP program.

    “The DSMB was asked to base their decision and it was their decision because we do not have access to the unblinded data to look at on efficacy PLA2R, which is the biomarker equivalent in membranous as Gd-IgA1 is to IgAN.”

    asked by Salveen Richter · answered by Reshma Kewalramani

    2 min read5 chapters

    Detailed Narrative

    01

    CF Franchise Continues to Set High Standards

    Vertex's CF franchise demonstrated strong performance, with ALYFTREK exceeding $1 billion in revenue in the first half of 2026. The company emphasized that ALYFTREK best restores CFTR function, with nearly two-thirds of younger patients achieving sweat chloride levels below 30 millimoles per liter, a threshold associated with CF carriers. This performance sets an exceptionally high bar for next-generation CFTR modulators, requiring them to demonstrate superior efficacy in reaching even more patients at these carrier levels.

    02

    Advancements in Renal Pipeline with Pove and Inaxaplin

    The renal pipeline saw significant progress, highlighted by the FDA's acceptance of the BLA for Pove in IgAN, with a PDUFA date of November 30, 2026. Management expressed confidence in Pove's potential, citing strong Phase III interim analysis data showing significant proteinuria reductions and a favorable safety profile. Additionally, the OLYMPUS Phase II/III trial for Pove in membranous nephropathy advanced to Phase III with an 80mg dose, and the AMPLITUDE Phase III study for inaxaplin in AMKD is on track for full enrollment by year-end, with interim analysis results expected in early 2027.

    03

    Strategic Progress in Type 1 Diabetes Program

    Vertex resumed dosing in the zimislecel Phase I/II/III study for type 1 diabetes and received IND clearance for VX-017, its universal donor (Type O) cell product. The company aims to accelerate the VX-017 program, potentially launching it first or very close to zimislecel, effectively doubling the addressable market opportunity from 60,000 to 120,000 patients. Updated timelines and regulatory strategies for the T1D program are expected in the second half of 2026.

    04

    Crinetics Acquisition Expands Therapeutic Pillars

    The announced acquisition of Crinetics Pharmaceuticals for approximately $8.8 billion net of cash acquired is expected to close in Q3 2026. This strategic move establishes rare endocrine diseases as Vertex's fifth therapeutic pillar, adding PALSONIFY and Atumelnant, which together represent a peak sales opportunity of about $5 billion. The transaction is anticipated to be accretive to non-GAAP operating income by 2029, reinforcing Vertex's long-term growth and earnings profile.

    05

    JOURNAVX Launch Dynamics and Payer Access

    JOURNAVX continues to gain traction with strong prescription growth, totaling approximately 535,000 in Q2 2026 and over 900,000 in H1 2026, ahead of forecast. However, the launch has seen higher-than-expected utilization of the patient support program (PSP) due to payer restrictions, impacting gross-to-net normalization, now anticipated in H1 2027. Despite this, the company is pleased with hospital adoption (1,400 hospitals) and expanding payer coverage, including two new Medicare Part D plans.

    AI-generated summary of the company’s earnings call. Not investment advice.